• Capsazepine: TRPV1 Ion Channel Antagonist in Pain Research

  2026-06-17

  Capsazepine, a synthetic TRPV1 ion channel antagonist, empowers researchers to dissect nociceptive and apoptotic pathways with precision. This guide offers actionable workflows, troubleshooting strategies, and evidence-based tips for maximizing its utility in pain and cancer research models.

• GLP-1 (9-36) amide: Optimizing GLP-1R Antagonism in Metaboli

  2026-06-16

  GLP-1 (9-36) amide empowers researchers to dissect GLP-1 receptor signaling with precision, enabling advanced metabolic and type 2 diabetes models. This guide translates bench-level workflows, troubleshooting, and assay innovation for maximum reproducibility and insight.

• Capsaicin ((E)-Capsaicin): Optimizing TRPV1 & KDM1A Assays

  2026-06-16

  Capsaicin ((E)-Capsaicin) uniquely enables dual interrogation of TRPV1 ion channel activation and KDM1A/LSD1 inhibition in translational models of pain, inflammation, and cancer. This guide delivers protocol-ready workflow enhancements, troubleshooting tips, and evidence-mapped insights to maximize experimental reproducibility and assay precision with APExBIO's validated Capsaicin.

• Topological Stress Induces Persistent rDNA Damage via PML-Nu

  2026-06-15

  This study reveals that topological stress and RNA polymerase I inhibition induce persistent DNA lesions in ribosomal DNA, leading to the formation of PML-nucleolar associations (PNAs). The findings clarify how these nuclear structures are triggered by specific DNA damage and repair pathway engagement, deepening our understanding of genome stability and cellular senescence.

• SAF312 as a Potent TRPV1 Antagonist for Ocular Surface Pain

  2026-06-15

  The reference study introduces SAF312 (Libvatrep) as a selective and potent TRPV1 antagonist, addressing a significant gap in ocular surface pain management. Through rigorous preclinical pharmacology and toxicology assessments, SAF312 demonstrates high TRPV1 selectivity, safety, and no impairment of corneal wound healing, supporting its potential for clinical development.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Pre

  2026-06-14

  DIDS, a benchmark anion transport inhibitor, empowers precision dissection of chloride channel biology and downstream physiological effects. This guide details optimized workflows, advanced applications, and troubleshooting strategies for leveraging DIDS in cancer, neuroprotection, and vascular research, supported by cutting-edge evidence.

• Resiniferatoxin (RTX): Data-Driven Solutions for Lab Pain Mo

  2026-06-13

  This article addresses real-world laboratory challenges in pain mechanism research, with scenario-driven guidance on optimizing cell-based and animal assays using Resiniferatoxin (RTX), SKU BA7012. It synthesizes current literature, protocol best practices, and vendor selection criteria to support reproducible results and informed adoption of RTX in biomedical workflows.

• ER Stress-Driven Prometastatic States in Tumor Cells: Mechan

  2026-06-12

  Conod et al. reveal that tumor cells surviving near-lethal stress can acquire stable prometastatic states (PAMEs) via ER stress, nuclear reprogramming, and a cytokine storm. This mechanistic insight reframes how metastases originate and suggests new intervention points for cancer therapy.

• Angiotensin III: Applied Workflows for RAAS and Viral Resear

  2026-06-12

  Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe) is reshaping cardiovascular and neuroendocrine research with its dual role as a pressor activity mediator and aldosterone secretion inducer. Recent cross-domain studies highlight its untapped potential in viral pathogenesis assays, making it an essential tool for advanced experimental modeling.

• IWP-2 (SKU A3512): Reliable Wnt Inhibition for Cell Assays

  2026-06-11

  This scenario-driven guide demonstrates how IWP-2 (SKU A3512), a potent Porcupine inhibitor, can resolve common laboratory challenges in cell viability, proliferation, and apoptosis assays. Evidence-backed analysis clarifies protocol parameters, data interpretation, and vendor selection, ensuring biomedical researchers achieve reproducible, high-impact results with IWP-2.

• Dabigatran Etexilate: Clinical Advances in Direct Thrombin I

  2026-06-11

  The referenced clinical review introduces Dabigatran etexilate as the first oral direct thrombin inhibitor approved for stroke and VTE prevention, addressing limitations of traditional anticoagulants. Its predictable pharmacology and lack of need for routine monitoring represent a significant advance in anticoagulant therapy, particularly for atrial fibrillation research and patient care.

• Pyridostatin TFA: Optimizing G-Quadruplex Research Workflows

  2026-06-10

  Pyridostatin TFA is transforming how scientists probe telomere biology and DNA secondary structures by enabling robust and selective G-quadruplex stabilization. This article delivers actionable protocol enhancements, advanced troubleshooting, and cross-domain insights rooted in landmark studies—empowering cancer and neurodegeneration research alike.

• Capsazepine: TRPV1 Ion Channel Antagonist in Pain Models

  2026-06-10

  Capsazepine, a potent TRPV1 antagonist, enables high-precision dissection of nociceptive and apoptotic pathways in translational pain and cancer research. This article details workflow optimizations, troubleshooting, and cross-comparisons for leveraging Capsazepine in advanced in vitro and ex vivo assays.

• Resiniferatoxin (RTX): Optimizing TRPV1 Pain and Inflammatio

  2026-06-09

  Resiniferatoxin (RTX) unlocks unprecedented selectivity and potency for TRPV1-driven pain, providing robust chemical inactivation of sensory neurons in both neuropathic and osteoarthritis models. This in-depth guide outlines actionable workflows, advanced troubleshooting, and novel immune insights for maximizing RTX’s translational value.

• Iptacopan (LNP023): Applied Workflows for Complement Researc

  2026-06-09

  Iptacopan (LNP023) delivers precise, selective inhibition of complement factor B, streamlining both in vitro and animal models of alternative pathway-driven disease. This article translates recent research breakthroughs into actionable protocols, troubleshooting guidance, and comparative insights for robust complement activation studies.

14712 records 1/981 page Next 12345 下5页 Last page